|

sac-TMT Clinical Trials

1 actively recruiting trial across 1 location

Also known as: MK-2870, Sacituzumab tirumotecan

Pipeline

Phase 3: 1

Top Sponsors

  • Merck Sharp & Dohme LLC1

Indications

  • NSCLC1
  • Lung Cancer1
  • Non Small Cell Lung Cancer1
  • Cancer1

Little Rock, Arkansas1 trial

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

CARTI Cancer Center ( Site 0006)

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.